Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

North Immunology announced an oversubscribed $180 million financing to advance NOR-101, a half-life-extended anti-IL-13 x IL-18 bispecific antibody for atopic dermatitis. The program is designed to target both type 2 and non-type 2 inflammation, positioning it as a potential best-in-disease treatment candidate. The sizable capital raise strengthens the company’s ability to fund clinical development in a competitive dermatology biologics market.